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Abstract
Aims. Psychosis spectrum disorder has a complex pathoetiology characterised by interacting
environmental and genetic vulnerabilities. The present study aims to investigate the role of
gene–environment interaction using aggregate scores of genetic (polygenic risk score for
schizophrenia (PRS-SCZ)) and environment liability for schizophrenia (exposome score for
schizophrenia (ES-SCZ)) across the psychosis continuum.
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Methods. The sample consisted of 1699 patients, 1753 unaffected siblings, and 1542 healthy
comparison participants. The Structured Interview for Schizotypy-Revised (SIS-R) was admi-
nistered to analyse scores of total, positive, and negative schizotypy in siblings and healthy
comparison participants. The PRS-SCZ was trained using the Psychiatric Genomics
Consortiums results and the ES-SCZ was calculated guided by the approach validated in a pre-
vious report in the current data set. Regression models were applied to test the independent
and joint effects of PRS-SCZ and ES-SCZ (adjusted for age, sex, and ancestry using
10 principal components).
Results. Both genetic and environmental vulnerability were associated with case-control sta-
tus. Furthermore, there was evidence for additive interaction between binary modes of PRS-
SCZ and ES-SCZ (above 75% of the control distribution) increasing the odds for schizophre-
nia spectrum diagnosis (relative excess risk due to interaction = 6.79, [95% confidential inter-
val (CI) 3.32, 10.26], p < 0.001). Sensitivity analyses using continuous PRS-SCZ and ES-SCZ
confirmed gene–environment interaction (relative excess risk due to interaction = 1.80 [95%
CI 1.01, 3.32], p = 0.004). In siblings and healthy comparison participants, PRS-SCZ and
ES-SCZ were associated with all SIS-R dimensions and evidence was found for an interaction
between PRS-SCZ and ES-SCZ on the total (B = 0.006 [95% CI 0.003, 0.009], p < 0.001),
positive (B = 0.006 [95% CI, 0.002, 0.009], p = 0.002), and negative (B = 0.006, [95% CI
0.004, 0.009], p < 0.001) schizotypy dimensions.
Conclusions. The interplay between exposome load and schizophrenia genetic liability con-
tributing to psychosis across the spectrum of expression provide further empirical support to
the notion of aetiological continuity underlying an extended psychosis phenotype.
Introduction
The psychosis spectrum ranges from serious, enduring, and disab-
ling illness to transient, sub-threshold psychotic experiences in
non-clinical populations (Guloksuz and van Os 2018). It repre-
sents a wide range of symptoms including aberrant thinking
and reasoning, perceptual abnormalities, cognitive disturbance,
as well as motivational and social deficits. Consistent with the
extended psychosis phenotype model, prevalence is estimated at
5–8% for psychotic experiences in the general population, 3%
for clinical psychotic disorders, and 0.5% for arguably the most
severe end of the spectrum meeting diagnostic criteria for schizo-
phrenia (van Os et al., 2009).
The aetiological and pathophysiological theories of psychosis
spectrum have evolved to encompass genetic and environmental
factors and their interaction (EUGEI investigators, 2014). The
concordance rates between twin pairs suggest the presence of gen-
etic factors with heritability estimates of up to 80% for schizo-
phrenia and 73% for the wider phenotype (Hilker et al., 2018).
More recent molecular genetic studies have confirmed that
schizophrenia spectrum disorder, as a common complex trait,
has a polygenic architecture, which is mainly shaped by many
common allele variants with small effect sizes that are normally
distributed among the general population (Schizophrenia
Working Group of the Psychiatric Genomics Consortium,
2014). With the advent of the genome-wide association study
approach, the Psychiatric Genomics Consortium has identified
145 significant loci associated with schizophrenia (Pardinas
et al., 2018). It is now possible to calculate an individual score
summarising the level of genetic risk for schizophrenia, known
as polygenic risk score for schizophrenia (PRS-SCZ) (Pardinas
et al., 2018).
Similarly, several environmental exposures have been asso-
ciated with a schizophrenia spectrum disorder, such as childhood
adversities, cannabis use, urbanicity, migration, ethnic minorities,
hearing impairment, and perinatal factors (Linszen et al., 2016;
Radua et al., 2018; Stilo and Murray, 2019). In accordance with
the diathesis-stress model, there is evidence supporting gene–
environment interaction in the aetiology of schizophrenia
(Guloksuz et al., 2019) and mood disorders (Geoffroy et al.,
2013; Colodro-Conde et al., 2018; Arnau-Soler et al., 2019a,
2019b). A recent case-control study found evidence for additive
interactions between molecular genetic liability for schizophrenia
(i.e. PRS-SCZ) and emotional abuse, emotional neglect, sexual
abuse, bullying, and regular cannabis use, suggesting that a multi-
tude of environmental factors and PRS-SCZ are independently
and jointly associated with schizophrenia (Guloksuz et al., 2019).
To better accommodate the multiplicity of exposures asso-
ciated with schizophrenia (Guloksuz et al., 2018), a cumulative
environmental exposure score for schizophrenia – exposome
score for schizophrenia (ES-SCZ) – was recently designed and
validated through predictive modelling approaches in training
and validation data sets of two independent cohorts that followed
identical measurement methods for environmental exposures
(Pries et al., 2019). This summary measure is generated using
weighted coefficients derived from a single model to take into
account the interdependency of exposures. Therefore, ES-SCZ
prevents overestimation of the weights per exposure that are likely
to occur when correlations between exposures are ignored, e.g.
weighted estimates of individual exposures from meta-analyses
or simple summation of exposures. Recent studies indicate that
the ES-SCZ is associated with psychosis risk states (Guloksuz
et al., 2020) as well as mental and physical health (Pries et al.,
2020b) in the general population.
By leveraging aggregate scores of genetic (PRS-SCZ) and envir-
onmental liability (ES-SCZ) in the current study and in accord-
ance with a previous study (Guloksuz et al., 2019), we aimed to
test gene–environment interaction across the psychosis spectrum
in a multinational multicentre sample of patients diagnosed
with schizophrenia spectrum disorder, their siblings, and healthy
comparison participants.
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Methods
Study population
Data were derived from the Workpackage 6 (WP6) of the
European Network of National Networks studying Gene–
Environment Interactions in Schizophrenia (EUGEI) and the
Genetic Risk and Outcome for Psychosis (GROUP) studies, col-
lected using uniform assessment schedules between 2010 and
2015 in the Netherlands, Turkey, Spain, and Serbia (Korver
et al., 2012). Both projects were approved by the Medical Ethics
Committees of all participating sites and conducted in accordance
with the Declaration of Helsinki. All respondents provided writ-
ten informed consent and, in the case of minors, such a consent
was also obtained from parents or legal guardians. Patients were
diagnosed with schizophrenia spectrum disorders according to
the DSM-IV-TR (average duration of illness since the age of the
first contact with mental health services = 9.9 years). Unrelated
controls with no lifetime psychotic disorder were recruited from
the same population as the cases. Exclusion criteria for all parti-
cipants were a diagnosis of psychotic disorder due to another
medical condition, a history of head injury with loss of conscious-
ness, and an intelligence quotient <70.
EUGEI WP6 (‘vulnerability and severity’) was a cross-sectional
study specifically conducted to investigate the role of gene–envir-
onment interaction of the vulnerability and severity of schizo-
phrenia spectrum disorder and its intermediate phenotypes in a
family-based setting.
GROUP is a naturalistic longitudinal cohort study that started
in 2004 in the Netherlands and Dutch-speaking part of Belgium
and collected data at baseline, 3 and 6 years follow-ups over an
approximate 10-year period, with the aim of studying the inter-
play of genetic and environmental factors impacting vulnerability
and resilience in psychotic disorders. Individuals in the sibling
group who manifested lifetime psychotic disorder over the study
period were reassigned to the patient group.
Further details of the GROUP and EUGEI projects are pro-
vided elsewhere (Korver et al., 2012; EUGEI investigators 2014).
The current analyses used a merged data set of GROUP baseline
data and EUGEI WP6 cross-sectional data including 1699
patients, 1753 siblings, and 1542 unrelated healthy comparison
participants who were of Caucasian white ethnic origin and had
available genotype data.
Outcomes
Diagnosis of schizophrenia spectrum disorder
Patients were diagnosed with schizophrenia spectrum disorders
according to the DSM-IV-TR. The diagnosis was confirmed by
the Operational Criteria Checklist for Psychotic and Affective
Illness (McGuffin et al., 1991) in EUGEI WP6, and by the
Schedules for Clinical Assessment in Neuropsychiatry (Wing
et al., 1990) and the Comprehensive Assessment of Symptoms
and History (Andreasen et al., 1992) in GROUP.
Schizotypy trait
In both GROUP and EUGEI, the Structured Interview for
Schizotypy-Revised (SIS-R) was administered to siblings and
healthy comparison participants. The SIS-R is a semi-structured
interview containing 20 schizotypal symptoms and 11 schizotypal
signs rated on a four-point scale (Kendler et al., 1989; Vollema
and Ormel, 2000). Symptoms are defined as verbal responses to
standardised questions concerning, for example, magical ideation,
illusions, and referential thinking. Signs refer to behaviours that
are rated by the interviewer such as goal-directedness of thinking
and flatness of effect. Questions and rating procedures are stan-
dardised. Guided by previous research, 31 item scores were
reduced a priori to two-dimensional scores representing the
means of seven positive schizotypy items (covering the areas of
referential thinking, psychotic phenomena, derealisation, magical
ideation, illusions, and suspiciousness) and eight negative/disor-
ganised schizotypy items (covering the areas of social isolation,
sensitivity, introversion, restricted affect, disturbances in associa-
tive and goal-directed thinking, poverty of speech, and eccentric
behaviour) (van Os et al., 2020).
Genetic and environmental liability measures
Exposome score for schizophrenia
The exposome score in the current analyses was calculated based
on our previously validated estimates (Pries et al., 2019) for con-
structing cumulative environmental load in this data set. Using
the log odds from our previous report, we generated the
ES-SCZ by summing log-odds weighted environmental exposures
(each exposure defined as absent = ‘0’ and present = ‘1’) including
cannabis use, hearing impairment, winter-birth, and childhood
adversity domains (emotional and physical neglect, emotional,
physical and sexual abuse, and bullying). The definition of each
exposure conformed to previous work in this data set.
Childhood adversities were assessed using the Childhood
Trauma Questionnaire (CTQ) Short Form (Bernstein et al.,
2003). This consists of 28 items, rated on a five-point Likert
scale, measuring five domains of maltreatment (emotional and
physical neglect; emotional, physical, and sexual abuse). The psy-
chometric characteristics of the translated versions (Spanish,
Turkish, Dutch, and Serbian) of the CTQ have been comprehen-
sively studied (Sar et al., 2004; Thombs et al., 2009; Hernandez
et al., 2013). To dichotomise each childhood adversity domain
(0 = ‘absent’ and 1 = ‘present’), consistent with previous work in
the EUGEI (Guloksuz et al., 2019), we used the following cut-off
scores for each domain: ⩾9 for emotional abuse; ⩾8 for physical
abuse; ⩾6 for sexual abuse; ⩾10 for emotional neglect; and ⩾8 for
physical neglect.
Cannabis use was assessed by a modified version of the
Cannabis Experiences Questionnaire (Barkus et al., 2006) in the
EUGEI WP6 (0 = ‘none’; 1 = ‘only once or twice’; 2 = ‘a few
times a year’; 3 = ‘a few times a month’; 4 = ‘once or more a
week’; 5 = ‘everyday’), and by the L section of the Composite
International Diagnostic Interview (Robins et al., 1988) in
the GROUP (0 = ‘none’; 1 = ‘less than weekly’; 2 = ‘weekly’;
3 = ‘daily’). Consistent with previous work (van Winkel et al.,
2011; Pries et al., 2018; Guloksuz et al., 2019; Radhakrishnan
et al., 2019), a binary regular cannabis use variable was
constructed by using the cut-off value of one or more per week
during the lifetime period of most frequent use.
In accordance with previous studies investigating the associ-
ation between season of birth and schizophrenia in the
Northern hemisphere sites (Davies et al., 2003), the high-risk
birth period was defined based on the winter solstice
(December–March), and a binary winter-birth exposure was con-
structed. Hearing impairment was defined based on self-reported
hearing impairment in the last 12 months (0 = ‘absent’ and
1 = ‘present’).
The history of bullying by peers (emotional, psychological or
physical violence) before 17 years of age was assessed using the
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short version of the Retrospective Bullying Questionnaire (Hunter
et al., 2004; Schäfer et al., 2004) that measures the severity of the
bullying experience: 0 = ‘none’; 1 = ‘some (no physical injuries)’; 2
= ‘moderate (minor injuries or transient emotional reactions)’; 3
= ‘marked (severe and frequent physical or psychological harm)’.
Exposure to childhood bullying was dichotomised using ⩾1 as the
cut-off point (0 = ‘absent’ and ⩾1 = ‘present’).
Polygenic risk score for schizophrenia
Samples of all individuals were genotyped at Cardiff University
Institute of Psychological Medicine and Clinical Neurology,
using a custom Illumina HumanCoreExome-24 BeadChip geno-
typing arrays containing probes for 5 70 038 genetic variants
(Illumina, San Diego, CA). Genotype data were called using the
GenomeStudio package and transferred into PLINK format for
further analysis. Quality control was conducted in PLINK v1.07
(Purcell et al., 2007) or with custom Perl scripts. Variants with
a call rate <98% were excluded from the data set. Hardy–
Weinberg equilibrium p value was calculated separately in
Turkish, northern European, and southern European samples.
Variants with Hardy–Weinberg equilibrium p value <1 × 10−6
in any of these three regions were excluded from the data set.
After QC, 5 59 505 variants remained. Samples with a call rate
<98% were excluded from the data set. A linkage disequilibrium
pruned set of variants was calculated using the – indep-pairwise
command in PLINK (maximum r2 = 0.25, window size = 500 sin-
gle nucleotide polymorphisms (SNPs), window step size = 50
SNPs) and used for further analyses. Homozygosity F values
were calculated using the – het command in PLINK, and outlier
samples (F <−0.11 or F > 0.15) were excluded. The genotypic sex
of samples was calculated from X chromosome data using the
check-sex command in PLINK, and samples with different geno-
typic sex to their database sex were excluded. Identity-by-descent
values were calculated for the sample in PLINK. Samples with one
or more siblings among the genotyped samples according to the
database but no identified genotypic siblings (defined as p̂
>0.35 and <0.65) were excluded. After these were removed from
consideration, samples with two or more siblings in the database
that were not supported by the genotypic data were also excluded.
After visually observing the clustering of errors by genotyping
chips, we decided to exclude chips with a high proportion of
errors. All samples on chips with five or more sample exclusions
due to heterozygosity or call rate (out of 12 possible samples) were
excluded. All samples on chips with four or more sample exclu-
sions due to sex or relative checks were also excluded unless
their identity was corroborated by concordance between database
and genotype relatedness data with a sample on another chip.
Principal components (PCs) were calculated in PLINK using link-
age disequilibrium (LD) pruned variants after combining the data
set with the Thousand Genomes reference data set. After quality
control, genotypes were imputed on the Michigan Imputation
Server using the Haplotype Reference Consortium reference
panel (version 1.1) and the programmes Eagle for haplotype phas-
ing and Minimac3 for imputation (Das et al., 2016; Loh et al.,
2016). After imputation, variants with an imputation r2 > 0.6,
minor allele frequency (MAF) > 0.1% and call rate >99% were
retained (82 77 535 variants). Best-guess genotypes were gener-
ated from genotype probabilities using PLINK.
PRS-SCZ was constructed using summary statistics from the
Psychiatric Genomics Consortium (PGC2) genome-wide associ-
ation study in both samples (Schizophrenia Working Group of
the Psychiatric Genomics Consortium, 2014). There was no
overlap between the PGC2 and the current data sets. Clumping
was performed in imputed best-guess genotypes for each data
set using PLINK (maximum r2 = 0.2, window size = 500 kb, min-
imum MAF = 10%, minimum INFO score = 0.7), and variants
within regions of long-range LD around the genome (including
the major histocompatibility complex) excluded (Price et al.,
2008). PRS-SCZ were then constructed from best-guess genotypes
using PLINK at 10 different p-value thresholds (PT = 1, 0.5, 0.3,
0.2, 0.1, 0.05, 0.01, 1 × 10−4, 1 × 10−6, 5 × 10−8). Consistent with
previous research in the field (Allardyce et al., 2018; Sorensen
et al., 2018) and previous work in this data set, we used PT =
0.05 for our primary analysis, as this threshold optimally captures
liability to the disorder in the Psychiatric Genomics Consortium
analysis (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014).
Statistical analysis
Stata software version 15.0 was used for the analysis (StataCorp,
2017). Supplementary Table S1 reports missing data. The analyses
were conducted on both multiple imputed data and raw data.
Under the assumption of missing at random, the multiple imput-
ation chained equation (Royston and White, 2011) was applied
with 20 imputations restricted to in-range values (relative effi-
ciency ⩾ 99%). ES-SCZ was calculated after imputing missing
values of the environmental exposures (cannabis use, hearing
impairment, winter-birth, and childhood adversity domains).
All the analyses were run on multiple imputed data and pooled
using Rubin’s rules (Rubin, 2004). To test gene–environment
interaction, additive models were chosen over multiplicative mod-
els prior to data collection (EUGEI consortium meeting, 14
December 2013), consistent with previous work (Guloksuz
et al., 2019), and given that they provide a superior representation
of biological synergy (Rothman, 1976) and inform public health
decisions within the sufficient cause framework (Rothman et al.,
1980; Kendler and Gardner, 2010). For all analyses, random inter-
cept multilevel mixed regression models, taking into account the
clustering of participants within countries, were applied. Models
including PRS-SCZ were a priori adjusted for ancestry using 10
PCs and adjusted models included age and sex as covariates.
The nominal significance threshold was set to p = 0.05.
For the case-control analyses, as utilised in previous studies
(Guloksuz et al., 2019; Guloksuz et al., 2020), ES-SCZ and
PRS-SCZ were dichotomised at the quartile cut-off points based
on the control distribution within each country (to account for
differences between countries that may arise due to ethnic and
geographical variation). The highest quartile was considered the
binary risk state for schizophrenia (hereafter PRS-SCZ75 and
ES-SCZ75). Multilevel logistic regression models were applied to
test the independent and joint effects of PRS-SCZ75 and
ES-SCZ75 (independent variables) on the diagnosis of schizophre-
nia (i.e. case-control status; dependent variable). Departure from
additivity was tested using the relative excess risk due to inter-
action (RERI) (Knol and VanderWeele, 2012; VanderWeele and
Knol, 2014). RERI greater than zero was defined as a positive
deviation from additivity and considered significant when the
95% confidence interval (CI) did not contain zero. Conforming
to early work in this sample, we applied the delta method to cal-
culate the RERI using the odds ratios derived from the model
(Guloksuz et al., 2019). Furthermore, sensitivity analyses were
conducted using the bootstrap percentile method to estimate
additive interaction between continuous PRS-SCZ and ES-SCZ
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in unimputed data (N = 1000 bootstrap replications) (Richardson
and Kaufman, 2009).
In unaffected siblings and healthy comparison participants,
the effects of continuous measures of PRS-SCZ, ES-SCZ, and
their interaction on continuous measures of schizotypy dimen-
sions (total, positive, and negative) as dependent variables were
tested with multilevel linear regression models, where the coeffi-
cient of the product term (PRS-SCZ×ES-SCZ) reflects the depart-
ure from additivity (Knol et al., 2007).
Previous analyses did not indicate a gene–environment cor-
relation between the individual environmental exposures and
PRS-SCZ75 in the control sample (Guloksuz et al., 2019).
Furthermore, for the current analyses, we tested gene–environ-
ment correlation between the continuous (ES-SCZ and
PRS-SCZ) and dichotomised (ES-SCZ75 and PRS-SCZ75) expo-
some and genetic risk scores applying multilevel linear and
logistic regression, respectively. Nagelkerke’s R2 was calculated
based on logistic regression with case-control status as the
dependent variable.
Results
Sample demographic data, SIS-R scores, PRS-SCZ75 and
ES-SCZ75 distributions are reported in Table 1. Missing data are
reported in the Supplementary material (Table S1).
PRS-SCZ explained 15% of the variance in case-control
status (OR = 1.30 [95% CI 1.25, 1.34], p < 0.001) and 20% after
adjusting for age, sex, and country (OR = 1.30 [95% CI 1.26,
1.35], p < 0.001). ES-SCZ explained 28% of the variance in case-
control status (OR = 2.52 [95% CI 2.29, 2.78], p < 0.001) and
33% after adjusting for age, sex, and country (OR = 2.40 [95%
CI 2.17, 2.66], p < 0.001).
There was no evidence for gene–environment correlation, as
PRS-SCZ75 was not strongly or significantly associated with
ES-SCZ75 in the control group (OR = 1.08 [95% CI 0.78, 1.51],
p = 0.635), neither after adjusting for age and sex (OR = 1.08
[95% CI 0.78, 1.51], p = 0.638) nor when using the continuous
scores; PRS-SCZ and ES-SCZ (B =−0.008 [95% CI −0.028,
0.013], p = 0.478; adjusted B =−0.008 [95% CI −0.029, 0.012],
p = 0.429).
Main and joint effects of PRS-SCZ75 and ES-SCZ75 on
case-control status
PRS-SCZ75 was associated with case status (OR = 2.91 [95% CI
2.48, 3.40], p < 0.001; adjusted for age and sex: OR = 2.85 [95%
CI 2.43, 3.35], p < 0.001); and ES-SCZ75 was associated with
case status (OR = 4.99 [95% CI 4.22, 5.90], p < 0.001, adjusted
for age and sex: OR = 4.90 [95% CI 4.14, 5.81], p < 0.001).
There was evidence for a positive additive interaction between
PRS-SCZ75 and ES-SCZ75 (RERI = 7.29 [95% CI 3.73, 10.85],
p < 0.001), also after adjusting for age and sex (Table 2 and
Fig. 1). Sensitivity analyses using continuous PRS-SCZ and
ES-SCZ confirmed G × E interaction (RERI = 1.77 [95% CI 1.00,
3.24], p = 0.003; adjusted RERI = 1.80 [95% CI 1.01, 3.32], p =
0.004). Results from the analyses using unimputed data corrobo-
rated these results and are reported in the Supplementary material
(Table S2 and Figure S3).
Main and joint effects of continuous PRS-SCZ and ES-SCZ on
SIS-R dimensions
PRS-SCZ was significantly associated with the SIS-R dimensions
in the unaffected sibling/healthy comparison participants sample
Table 1. Sample characteristics
Patients n = 1699 Siblings n = 1753 Controls n = 1542 Total N = 4994
Age Mean (S.D.) 31.49 (8.95) 31.73 (9.62) 33.45 (10.62) 32.18 (9.76)
Sex % female 30.02 53.17 50.58 44.49
SIS-R total Mean (S.D.) – 0.39 (0.33) 0.23 (0.24) 0.32 (0.30)a
SIS-R positive Mean (S.D.) – 0.41 (0.42) 0.24 (0.31) 0.33 (0.38)a
SIS-R negative Mean (S.D.) – 0.38 (0.34) 0.23 (0.24) 0.31 (0.31)a
PRS-SCZ75 % > 75
th 45.44 33.09 23.74 34.40
ES-SCZ75 % > 75
th 58.79 36.30 21.88 37.64
ES-SCZ75, exposome score for schizophrenia (75% cut-point); n, number of individuals; PRS-SCZ75, polygenic risk score for schizophrenia (75% cut-point); S.D., standard deviation; SIS-R, the
structured interview for schizotypy – revised.
aWithin siblings and control groups (3295 individuals).
Table 2. Interaction of PRS-SCZ75 and ES-SCZ75 on case-control status
PRS-SCZ75 = 0 PRS-SCZ75 = 1
RERI (95% CI)Odds ratio (95% CI) Odds ratio (95% CI)
ES-SCZ75 = 0 1.0 2.79 (2.24–3.47)
P < 0.001
6.79 (3.32–10.26)
P < 0.001
ES-SCZ75 = 1 4.86 (3.92–6.02)
P < 0.001
13.44 (10.21–17.69)
P < 0.001
CI, confidence interval; ES-SCZ75, exposome score for schizophrenia (75% cut-point); PRS-SCZ75, polygenic risk score for schizophrenia (75% cut-point); RERI, relative excess risk due to
interaction.
Adjusted for sex, age, and ten PCs.
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(total: B = 0.011 [95% CI 0.006, 0.015], p < 0.001; positive:
B = 0.012 [95% CI 0.007, 0.018], p < 0.001; negative: B = 0.010
[95% CI 0.005, 0.014], p < 0.001) also after adjusting for age
and sex (Table 3). ES-SCZ was also significantly associated with
the SIS-R dimensions (total: B = 0.088 [95% CI 0.078, 0.098],
p < 0.001; positive: B = 0.103 [95% CI 0.090, 0.116], p < 0.001;
negative: B = 0.074 [95% CI 0.064, 0.085], p < 0.001), also after
adjusting for age and sex (Table 3). There was evidence for a sig-
nificant interaction between ES-SCZ and PRS-SCZ on the SIS-R
dimensions (total: B = 0.006 [95% CI 0.003, 0.009], p < 0.001;
positive: B = 0.005 [95% CI 0.002, 0.009], p = 0.002; and negative:
B = 0.006 [95% CI 0.003, 0.009], p < 0.001), also after adjusting for
age and sex (Table 3). Results from the analyses in unimputed
data confirmed the results in imputed data and are reported in
the Supplementary material (Table S4).
Discussion
To the best of our knowledge, this is the first study testing the role
of gene–environment interaction using aggregate scores of envir-
onmental and genetic liability across the spectrum of psychosis
expression. In the case-control design, we found evidence for
additive interaction between PRS-SCZ and ES-SCZ increasing
the odds for schizophrenia. Similarly, evidence emerged for inter-
action between PRS-SCZ and ES-SCZ on schizotypal traits when
investigating G×E interaction in the group of unaffected siblings
and healthy comparison participants.
By using aggregate scores for genetic and environmental liabil-
ity for schizophrenia, we provided further support for the role of
gene–environment interaction in schizophrenia spectrum dis-
order (Bernardo et al., 2017; Guloksuz et al., 2019) and replicated
recent findings of suggestive, but not nominally statistically sig-
nificant, additive interaction between PRS-SCZ and environmen-
tal risk score for schizophrenia in a first episode psychosis cohort
(Mas et al., 2020). When PRS-SCZ75 and ES-SCZ75 were analysed
as binary modes of risk factors, the relative excess risk due to the
interaction was 6.79 and the corresponding 95% CI was above 2,
suggesting a ‘mechanistic’ interaction, which means that the risk
of developing schizophrenia for some individuals exists only
when both genetic and environmental risks are present together
but not when either genetic or environmental risk is present
alone. The results further suggest that the PRS-SCZ and
ES-SCZ explain 15 and 28% of the variance in case-control sam-
ples, respectively.
In a previous study, we demonstrated that the extent of sub-
threshold phenotypic expression of schizophrenia polygenic risk
is contingent on having a sibling with a psychotic disorder, sug-
gesting a gene–environment interaction underlying schizotypy
expression (van Os et al., 2020). In the light of this new evidence,
we tested for the first time the putative role of gene–environment
Fig. 1. Additive effect of the polygenic risk score for
schizophrenia, 75% cut-point (PRS-SCZ75), and the
exposome score for schizophrenia, 75% cut-point
(ES-SCZ75) on case-control status, adjusted for age,
sex, and ten PCs; RERI: relative excess risk due to
interaction.
Table 3. Main and joint effects of PRS-SCZ and ES-SCZ on SIS-R scores
Psychopathology measures
Main effect PRS-SCZa Main effect ES-SCZ Interactiona
B 95% CI p-value B 95% CI p-value B 95% CI p-value
SIS-R total 0.011 0.007–0.015 <0.001 0.088 0.078–0.098 <0.001 0.006 0.003–0.009 <0.001
SIS-R positive 0.012 0.007–0.018 <0.001 0.103 0.091–0.116 <0.001 0.006 0.002–0.009 0.002
SIS-R negative 0.010 0.005–0.014 <0.001 0.074 0.064–0.085 <0.001 0.006 0.004–0.009 <0.001
B, regression coefficient from the multilevel model; CI, confidence interval; ES-SCZ, exposome score for schizophrenia; PRS-SCZ, polygenic risk score for schizophrenia; SIS-R, the structured
interview for schizotypy – revised.
All analyses were adjusted for age and sex.
aAdditionally adjusted for ten PCs.
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interaction in schizotypy traits. In line with our previous infer-
ence, we have now demonstrated that molecular genetic liability
for schizophrenia moderates the effect of environmental liability
for schizophrenia on phenotypic expression of overall, positive,
and negative schizotypy traits in unaffected participants.
Although much research has investigated the role of familial sen-
sitivity to individual environmental exposures (e.g. cannabis use
and childhood adversities) underlying subclinical psychosis
expression (Modinos et al., 2013; EUGEI investigators, 2014),
only a few studies have utilised PRS to investigate the role of
G×E in intermediate psychotic phenotypes (Ronald and Pain,
2018). A recent study from the 1966 Northern Finland Birth
Cohort showed that high birth weight, a risk factor for familial
schizophrenia in this cohort, increased the association between
PRS-SCZ and social anhedonia, suggesting a gene–environment
interaction (Liuhanen et al., 2018). Similarly, a study conducted
in a general population twin cohort demonstrated that while
PRS-SCZ was not independently associated with affective dysre-
gulation and psychosis proneness, PRS-SCZ increased sensitivity
to the effect of childhood adversities on affective dysregulation
and psychosis proneness (Pries et al., 2020a). Although not a dir-
ect test of gene–environment interaction, a study of healthy young
males assessed during their compulsory military service showed
that there was a negative association between PRS-SCZ and posi-
tive schizotypy at military induction (stressful condition) but not
at follow-up, providing further support for the key role of envir-
onment in the phenotypic expression of schizotypy traits
(Hatzimanolis et al., 2018). Taken together, although warranting
further replication in independent cohorts, these findings imply
that the phenotypic expression of schizotypical traits involves
underlying genomic liability for schizophrenia that operates, at
least in part, through sensitising individuals to the exposome.
The major strengths related to the study population were
threefold: sufficient sample size to detect gene–environment
interactions, access to comprehensive genotype, phenotype, and
exposure data collected through validated interviews conducted
by trained psychiatrists, psychologists or research assistants, and
the geographical and cultural diversity of the sample that may
increase the variation of environmental exposures and thereby
provide increased power and replicability to detect interaction
effects across populations (Ritz et al., 2017).
The ES-SCZ was constructed using predictive modelling that
mutually adjusted for the interdependency of exposures to prevent
overestimation of the weights per exposure. ES-SCZ was fully
compatible with this study population and clearly outperformed
other aggregate scores that were based on meta-analytical esti-
mates or simple summation of exposures as shown previously.
Notwithstanding, ES-SCZ was limited by the degree to which
exposures were available in the data set, and therefore did not
include other exposures that might be of importance, such as
obstetric and pregnancy complications (Garcia-Rizo and
Bitanihirwe, 2020). Furthermore, childhood adversities and can-
nabis use were retrospectively assessed and may be affected by
recall bias (Baldwin et al., 2019). Although population stratifica-
tion was controlled using PCs and no gene–environment correl-
ation was detected, unmeasured environmental confounding
might still be present. The cross-sectional design did not allow
for investigating the dynamic nature of gene–environment inter-
action over time.
In conclusion, we have shown that the interplay between expo-
some load and genetic liability for schizophrenia contributes to
the phenotypical expression of psychosis across the extended
phenotype. Our findings provide further empirical support to
the notion of aetiological continuity of psychosis spectrum and
pave the way for future longitudinal studies of schizotypy traits
in the general population. As some individuals may only develop
schizophrenia spectrum disorder if both the genetic and environ-
mental vulnerabilities are present, the current findings highlight
the importance of the combined effect of genomic and exposomic
liability for clinical practice. Furthermore, the results suggest that
health care strategies may benefit from focusing on modifiable
environmental factors.
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